Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2006-02-28
2006-02-28
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S155000, C564S163000, C564S164000, C564S166000, C514S616000, C514S617000, C514S619000
Reexamination Certificate
active
07005546
ABSTRACT:
A group of benzamide compounds are disclosed which are useful for treating neurodegenerative disorders. Methods for making these compounds are provided. These materials are formed into pharmaceutical compositions for oral or intravenous administration to patients suffering from conditions such as Parkinson's disease which can exhibit themselves as progressive loss of central nervous system function. The compounds can arrest or slow the progressive loss of function.
REFERENCES:
patent: 5472983 (1995-12-01), Flitter et al.
patent: 5643965 (1997-07-01), Flitter et al.
patent: 5658953 (1997-08-01), Flitter et al.
patent: 5659082 (1997-08-01), Flitter et al.
patent: 5756548 (1998-05-01), Flitter et al.
patent: 5914350 (1999-06-01), Flitter et al.
patent: 5955506 (1999-09-01), Flitter et al.
patent: 6077870 (2000-06-01), Flitter et al.
patent: 6509378 (2003-01-01), Flitter et al.
patent: 6759433 (2004-07-01), Flitter et al.
patent: 1 505 633 (1978-03-01), None
patent: 2 244 704 (1991-12-01), None
patent: 2 244 704 (1995-05-01), None
Banasik et al., “Specific inhibitors of poly(ADP-Ribose) synthetase and mono(ADP-ribosyl)transferase”J. Biol. Chem.(1992) 267:1569-1575.
Beal, M.F. inMitochondrial Dysfunction and Oxidative Damage in Neurodegenerative Diseases, R.G. Landes Publications Austin, TX, (1995) pp. 53-61 and 73-99.
Bishop et al., “Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D2receptors”J. Med. Chem.(1991) 34:1612-1624.
Burns, R.S., et al., “A Primate Model of Parkinsonism . . . ”Proc. Natl. Acad. Sci USA(1983) 80:4546-4550.
Calne, D.B., “Treatment of Parkinson's Disease”NEJM(Sep. 30, 1993) 329:1021-1027.
El Tayar, et al., “Interaction of neuroleptic drugs with rat striatal D-1 and D-2 dopamine receptors: a quantitative structure—affinity relationship study”Eur. J. Med. Chem.(1988) 23:173-182.
Gerlach, M. et al., “MPTP Mechanisms of Neurotoxicity and the Implications for Parkinson's Disease”European Journal of Pharmacology(1991) 208:273-286.
Heikkila, R.E., et al., “Dopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine in Mice”Science(Jun. 29, 1984) 224:1451-1453.
Högberg et al., “Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners”J. Med. Chem.(1991) 34:948-955.
Kato, T., “Reaction of Triethyloxonium Fluoroborate with Acid Amide. III11Formation of Quinazoline and 4H-3, 1-Benzoxazin-4-one Derivatives”,Chem. Pharm. Bull. (1976) 24. 3:431-436.
Katopodis et al., “Novel substrates and inhibitors of peptidylglycine α-amidating monooxygenase”Biochemistry(1990) 29:4541-4548.
Langston, J.W., et al., “Chronic Parkinsonism in Humans Due to Product of Meperidine-Analog Synthesis”Science(Feb. 25, 1983) 219, 979-980.
Marsden, C.D., in “Review Article—Parkinson's Disease”Lancet(Apr. 21, 1990) 948-952.
Mizuno, Y., Mori, H., Kondo, T. “Potential of Neuroprotective Therapy in Parkinson's Disease”CNS Drugs(1994) 1:45-46.
Monković et al., “Potential non-dopaminergic gastrointestinal prokinetic agents in the series of substituted benzamides”Eur. J. Med. Chem.(1989) 24:233-240.
Rainnie et al., “Adenosine inhibition of mesopontine cholinergic neurons: implications for EEG arousal”Science(1994) 263:689-690.
Singer, T.P., et al., “Biochemical Events in the Development of Parkinsonism . . . ”J. Neurochem.(1987) 1-8.
Patent Abstracts of Japan, vol. 006, No. 090 (C-104), May 27, 1982 & JP,A,57 021320 (Chugai Pharmaceut Co Ltd), Feb. 4, 1982, see abstract, see also Derwent abstract 82-20427E.
Patent Abstracts of Japan, vol. 007, No. 155 (C-175), Jul. 7, 1958 & JP,A,58 067657 (Chugai Seiyaku KK), Apr. 22, 1983, see abstract, see also Derwent abstract 83-52581K.
Flitter William
Garland William
Paylor Richard
Wilcox Allan
Klauber & Jackson
Kumar Shailendra
Renovis, Inc.
LandOfFree
Acetamidobenzamide compounds for neurodegenerative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acetamidobenzamide compounds for neurodegenerative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acetamidobenzamide compounds for neurodegenerative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3641643